Skip to main content
Top
Published in: Advances in Therapy 12/2020

Open Access 01-12-2020 | Underweight | Original Research

A Retrospective Cohort Study to Investigate the Incidence of Cachexia During Chemotherapy in Patients with Colorectal Cancer

Authors: Masayuki Shibata, Masaru Fukahori, Eiji Kasamatsu, Koji Machii, Satoshi Hamauchi

Published in: Advances in Therapy | Issue 12/2020

Login to get access

Abstract

Introduction

This retrospective study focused on cancer cachexia in clinical practice. We evaluated the incidence of cancer cachexia and the relationship between cancer cachexia and overall survival (OS) or toxicities in patients with advanced colorectal cancer after undergoing first-line systemic chemotherapy.

Methods

We examined 150 patients with colorectal cancer who underwent first-line systemic chemotherapy between February 1, 2010 and August 31, 2016 at Shizuoka Cancer Center Hospital and Kurume University Hospital. Cancer cachexia was defined as > 5% weight loss or > 2% weight loss with a body mass index of < 20 kg/m2 within the past 6 months according to the European Palliative Care Research Collaborative criteria.

Results

One hundred patients from Shizuoka Cancer Center and 50 from Kurume University Hospital were registered. Median age and body mass index were 65 years (range 29–85) and 21.7 kg/m2 (14.8–32.5), respectively. Cumulative incidence of cancer cachexia was 50.7% at 24 weeks, and reached 91.3% over the whole study period. OS was significantly different between patients with and without cancer cachexia within 24 weeks after starting first-line treatment, although the onset of cancer cachexia within 24 weeks could not be considered as an independent prognostic factor for OS. Severe appetite loss and fatigue tended to occur more frequently in patients with cancer cachexia within 24 weeks.

Conclusion

Cancer cachexia appears to have an onset in approximately half of patients with advanced colorectal cancer within 24 weeks after starting first-line treatment. Although causal relationships were controversial, the onset of cancer cachexia within 24 weeks tends to be related to worse outcomes. Thus, it would be better to monitor weight loss leading to cachexia in patients with advanced colorectal cancer, especially within 24 weeks after starting first-line chemotherapy.

Trial Registration

University Hospital Medical Information Network Clinical Trials Registry (UMIN000035002).
Appendix
Available only for authorised users
Literature
1.
go back to reference Baracos VE, Mazurak VC, Bhullar AS. Cancer cachexia is defined by an ongoing loss of skeletal muscle mass. Ann Palliat Med. 2019;8:3–12.CrossRef Baracos VE, Mazurak VC, Bhullar AS. Cancer cachexia is defined by an ongoing loss of skeletal muscle mass. Ann Palliat Med. 2019;8:3–12.CrossRef
2.
go back to reference Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–95.CrossRef Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–95.CrossRef
3.
go back to reference Bruggeman AR, Kamal AH, LeBlanc TW, Ma JD, Baracos VE, Roeland EJ. Cancer cachexia: beyond weight loss. J Oncol Pract. 2016;12:1163–71.CrossRefPubMed Bruggeman AR, Kamal AH, LeBlanc TW, Ma JD, Baracos VE, Roeland EJ. Cancer cachexia: beyond weight loss. J Oncol Pract. 2016;12:1163–71.CrossRefPubMed
4.
go back to reference Escamilla DM, Jarrett P. The impact of weight loss on patients with cancer. Nurs Times. 2016;112:20–2.PubMed Escamilla DM, Jarrett P. The impact of weight loss on patients with cancer. Nurs Times. 2016;112:20–2.PubMed
5.
go back to reference Lau SKM, Iyengar P. Implications of weight loss for cancer patients receiving radiotherapy. Curr Opin Support Palliat Care. 2017;11:261–5.CrossRefPubMed Lau SKM, Iyengar P. Implications of weight loss for cancer patients receiving radiotherapy. Curr Opin Support Palliat Care. 2017;11:261–5.CrossRefPubMed
6.
go back to reference Tarricone R, Ricca G, Nyanzi-Wakholi B, Medina-Lara A. Impact of cancer anorexia-cachexia syndrome on health-related quality of life and resource utilisation: a systematic review. Crit Rev Oncol Hematol. 2016;99:49–62.CrossRefPubMed Tarricone R, Ricca G, Nyanzi-Wakholi B, Medina-Lara A. Impact of cancer anorexia-cachexia syndrome on health-related quality of life and resource utilisation: a systematic review. Crit Rev Oncol Hematol. 2016;99:49–62.CrossRefPubMed
7.
go back to reference Sasaki S, Oki E, Saeki H, et al. Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A). Int J Clin Oncol. 2019;24:1204–13.CrossRefPubMed Sasaki S, Oki E, Saeki H, et al. Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A). Int J Clin Oncol. 2019;24:1204–13.CrossRefPubMed
8.
go back to reference Blum D, Omlin A, Fearon K, et al. Evolving classification systems for cancer cachexia: ready for clinical practice? Support Care Cancer. 2010;18:273–9.CrossRefPubMed Blum D, Omlin A, Fearon K, et al. Evolving classification systems for cancer cachexia: ready for clinical practice? Support Care Cancer. 2010;18:273–9.CrossRefPubMed
9.
go back to reference Kimura M, Naito T, Kenmotsu H, et al. Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer. Support Care Cancer. 2015;23:1699–708.CrossRefPubMed Kimura M, Naito T, Kenmotsu H, et al. Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer. Support Care Cancer. 2015;23:1699–708.CrossRefPubMed
10.
go back to reference Takayama K, Atagi S, Imamura F, et al. Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients—Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study. Support Care Cancer. 2016;24:3473–80.CrossRefPubMed Takayama K, Atagi S, Imamura F, et al. Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients—Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study. Support Care Cancer. 2016;24:3473–80.CrossRefPubMed
11.
go back to reference Mitsunaga S, Kasamatsu E, Machii K. Incidence and frequency of cancer cachexia during chemotherapy for advanced pancreatic ductal adenocarcinoma. Support Care Cancer. 2020;28:5271–9.CrossRefPubMed Mitsunaga S, Kasamatsu E, Machii K. Incidence and frequency of cancer cachexia during chemotherapy for advanced pancreatic ductal adenocarcinoma. Support Care Cancer. 2020;28:5271–9.CrossRefPubMed
13.
go back to reference Thoresen L, Frykholm G, Lydersen S, et al. Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results. Clin Nutr. 2012;32:65–72.CrossRef Thoresen L, Frykholm G, Lydersen S, et al. Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results. Clin Nutr. 2012;32:65–72.CrossRef
14.
go back to reference Wallengren O, Lundholm K, Bosaeus I. Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients. Support Care Cancer. 2013;21:1569–77.CrossRef Wallengren O, Lundholm K, Bosaeus I. Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients. Support Care Cancer. 2013;21:1569–77.CrossRef
15.
go back to reference Hamauchi S, Furuse J, Takano T, et al. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. Cancer. 2019;125:4294–302.CrossRefPubMed Hamauchi S, Furuse J, Takano T, et al. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. Cancer. 2019;125:4294–302.CrossRefPubMed
16.
go back to reference Kurk S, Peeters P, Stellato R, et al. Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients. J Cachex Sarcopenia Muscle. 2019;10:803–13.CrossRef Kurk S, Peeters P, Stellato R, et al. Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients. J Cachex Sarcopenia Muscle. 2019;10:803–13.CrossRef
17.
go back to reference Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980;69:491–7.CrossRef Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980;69:491–7.CrossRef
18.
go back to reference Miyamoto Y, Hiyoshi Y, Akiyama T, et al. Low skeletal muscle mass before salvage-line chemotherapy is a poor prognostic factor in patients with refractory metastatic colorectal cancer. Digestion. 2019;99:79–85.CrossRef Miyamoto Y, Hiyoshi Y, Akiyama T, et al. Low skeletal muscle mass before salvage-line chemotherapy is a poor prognostic factor in patients with refractory metastatic colorectal cancer. Digestion. 2019;99:79–85.CrossRef
19.
go back to reference Andreyev HJ, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer. 1998;34:503–9.CrossRef Andreyev HJ, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer. 1998;34:503–9.CrossRef
20.
go back to reference Antoun S, Morel H, Souquet P-J, et al. Staging of nutrition disorders in non-small-cell lung cancer patients: utility of skeletal muscle mass assessment. J Cachexia Sarcopenia Muscle. 2019;10:782–93.CrossRefPubMed Antoun S, Morel H, Souquet P-J, et al. Staging of nutrition disorders in non-small-cell lung cancer patients: utility of skeletal muscle mass assessment. J Cachexia Sarcopenia Muscle. 2019;10:782–93.CrossRefPubMed
21.
go back to reference Dell'Aquila E, Cremolini C, Zeppola T, et al. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO. Ann Oncol. 2018;29:924–30.CrossRefPubMed Dell'Aquila E, Cremolini C, Zeppola T, et al. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO. Ann Oncol. 2018;29:924–30.CrossRefPubMed
22.
go back to reference Steinberg J, Erlichman C, Gadalla T, Fine S, Wong A. Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. Eur J Cancer. 1992;28A:1817–20.CrossRefPubMed Steinberg J, Erlichman C, Gadalla T, Fine S, Wong A. Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. Eur J Cancer. 1992;28A:1817–20.CrossRefPubMed
23.
go back to reference Murphy RA, Mourtzakis M, Chu QSC, Baracos VE, Reiman T, Mazurak VC. Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer. 2011;117:1775–822.CrossRefPubMed Murphy RA, Mourtzakis M, Chu QSC, Baracos VE, Reiman T, Mazurak VC. Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer. 2011;117:1775–822.CrossRefPubMed
24.
go back to reference Mouri T, Naito T, Morikawa A, et al. Promotion of behavioral change and the impact on quality of life in elderly patients with advanced cancer: a physical activity intervention of the multimodal nutrition and exercise treatment for advanced cancer program. Asia Pac J Oncol Nurs. 2018;5:383–90.CrossRefPubMed Mouri T, Naito T, Morikawa A, et al. Promotion of behavioral change and the impact on quality of life in elderly patients with advanced cancer: a physical activity intervention of the multimodal nutrition and exercise treatment for advanced cancer program. Asia Pac J Oncol Nurs. 2018;5:383–90.CrossRefPubMed
25.
go back to reference Zopf Y, Schink K, Reijic D, et al. Assessing cachexia in older patients: different definitions – but which one is the most practical for clinical routine? Arch Gerontol Geriatr. 2020;86:103943.CrossRefPubMed Zopf Y, Schink K, Reijic D, et al. Assessing cachexia in older patients: different definitions – but which one is the most practical for clinical routine? Arch Gerontol Geriatr. 2020;86:103943.CrossRefPubMed
Metadata
Title
A Retrospective Cohort Study to Investigate the Incidence of Cachexia During Chemotherapy in Patients with Colorectal Cancer
Authors
Masayuki Shibata
Masaru Fukahori
Eiji Kasamatsu
Koji Machii
Satoshi Hamauchi
Publication date
01-12-2020
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 12/2020
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-020-01516-6

Other articles of this Issue 12/2020

Advances in Therapy 12/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.